Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study
Ruben A. Mesa(Atrium Health Wake Forest Baptist), Brady L. Stein(Barnes-Jewish Hospital), Shreekant Parasuraman(Incyte (United States)), Wei Peng(Incyte (United States)), Alison R. Moliterno(Johns Hopkins University), Joseph A. Cordaro(Incyte (United States)), Ahmad Naim(Incyte (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Haowei Sun(University of Alberta)
Cited by 2
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425